OBJECTIVE: To discuss the treatment and outcomes for cutaneous angiosarcoma. METHODS: Review of the pertinent literature. RESULTS: Cutaneous angiosarcoma is a rare, aggressive malignancy with a poor prognosis. It usually arises in the scalp or face and is locally advanced at presentation. Patients are most often white, male, and elderly. A subset of patients presents with multifocal disease and/or positive regional nodes. Although the optimal treatment is surgery followed by wide-field radiotherapy (RT), the disease is frequently so extensive at diagnosis that it is not completely resectable. Even after optimal local-regional treatment, there is a relatively high likelihood of a local recurrence at the margins of the RT fields. The probability of hematogenous dissemination is relatively high. Limited data suggest that chemotherapy may be useful for palliation with progression-free survival rates ranging from 1 to 5 months. The 5-year local-regional control rates are approximately 40% to 50%, the 5-year distant metastasis-free survival rates range from 20% to 40%, and the 5-year survival rates range from 10% to 30%. CONCLUSION: Cutaneous angiosarcoma is a rare, aggressive malignancy that is optimally treated with resection and wide-field postoperative RT. The likelihood of local-regional failure is high, as is the risk of distant relapse. Chemotherapy may be useful for short-term palliation.
OBJECTIVE: To discuss the treatment and outcomes for cutaneous angiosarcoma. METHODS: Review of the pertinent literature. RESULTS:Cutaneous angiosarcoma is a rare, aggressive malignancy with a poor prognosis. It usually arises in the scalp or face and is locally advanced at presentation. Patients are most often white, male, and elderly. A subset of patients presents with multifocal disease and/or positive regional nodes. Although the optimal treatment is surgery followed by wide-field radiotherapy (RT), the disease is frequently so extensive at diagnosis that it is not completely resectable. Even after optimal local-regional treatment, there is a relatively high likelihood of a local recurrence at the margins of the RT fields. The probability of hematogenous dissemination is relatively high. Limited data suggest that chemotherapy may be useful for palliation with progression-free survival rates ranging from 1 to 5 months. The 5-year local-regional control rates are approximately 40% to 50%, the 5-year distant metastasis-free survival rates range from 20% to 40%, and the 5-year survival rates range from 10% to 30%. CONCLUSION:Cutaneous angiosarcoma is a rare, aggressive malignancy that is optimally treated with resection and wide-field postoperative RT. The likelihood of local-regional failure is high, as is the risk of distant relapse. Chemotherapy may be useful for short-term palliation.
Authors: K Ogawa; K Takahashi; Y Asato; Y Yamamoto; K Taira; S Matori; S Iraha; N Yagi; A Yogi; S Haranaga; J Fujita; H Uezato; S Murayama Journal: Br J Radiol Date: 2012-07-17 Impact factor: 3.039
Authors: Matthew C Perez; Tapan A Padhya; Jane L Messina; Ryan S Jackson; Ricardo J Gonzalez; Marilyn M Bui; G Douglas Letson; C W Cruse; Robert S Lavey; David Cheong; Meghan R Forster; William J Fulp; Vernon K Sondak; Jonathan S Zager Journal: Ann Surg Oncol Date: 2013-07-09 Impact factor: 5.344
Authors: K Iwamoto; S Suzuki; A Kurata; K Sato; J Niki; T Miyazaki; S Utsuki; H Oka; K Fujii; S Kan; M Masuzawa Journal: Interv Neuroradiol Date: 2008-06-30 Impact factor: 1.610
Authors: Kim D Johnson; Olga V Glinskii; Valeri V Mossine; James R Turk; Thomas P Mawhinney; Douglas C Anthony; Carolyn J Henry; Virginia H Huxley; Gennadi V Glinsky; Kenneth J Pienta; Avraham Raz; Vladislav V Glinsky Journal: Neoplasia Date: 2007-08 Impact factor: 5.715
Authors: Daphna Laifenfeld; Annalyn Gilchrist; David Drubin; Milena Jorge; Sean F Eddy; Brian P Frushour; Bill Ladd; Leslie A Obert; Mark M Gosink; Jon C Cook; Kay Criswell; Christopher J Somps; Petra Koza-Taylor; Keith O Elliston; Michael P Lawton Journal: Toxicol Sci Date: 2009-10-07 Impact factor: 4.849